Monte Rosa Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $123.7M | $75.6M | $0 | — | — |
| Research and development | $141.5M | $121.6M | $111.3M | $85.1M | $57.2M |
| Operating expenses | $177.9M | $156.7M | $143.3M | $112.4M | $72.9M |
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M | -$72.9M |
| Pretax income | -$39.7M | -$70.1M | -$135.0M | -$108.5M | — |
| Income tax expense | -$1.1M | $2.6M | $338,000 | $0 | — |
| Net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M | -$74.0M |
| Balance Sheet | |||||
| Cash and equivalents | $129.9M | $224.3M | $128.1M | $54.9M | $346.1M |
| Current assets | $393.2M | $377.4M | $236.2M | $275.9M | $348.7M |
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M | $366.3M |
| Current liabilities | $64.2M | $156.9M | $46.6M | $25.6M | $16.6M |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M | $18.8M |
| Stockholders' equity | $233.1M | $222.9M | $179.2M | $271.4M | $347.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$22.8M | $42.0M | -$43.8M | -$92.5M | -$59.4M |
| Depreciation and amortization | $8.4M | $8.1M | $6.2M | $3.7M | $2.1M |
| Stock-based compensation | $18.9M | $18.1M | $16.7M | $11.7M | $5.2M |
| Capital expenditure | $4.7M | $4.0M | $19.0M | $12.9M | $9.7M |
| Free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M | -$69.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 84.5M · Free float 78.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.